Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease

morningstar.com·May 27, 2026 · 3 g fa

Rigel to Present at the Jefferies Global Healthcare Conference

ecodibergamo.it·May 29, 2026 · 1 g fa

RLS-1496 di Rubedo riduce le cheratosi attiniche, lesioni precancerose della pelle, del 46% dopo quattro settimane, con irritazione minima nei risultati preliminari dello studio di fase 1b/2a

ecodibergamo.it·May 29, 2026 · 19 h fa

BeOne Medicines definisce uno standard per il controllo della malattia a lungo termine nella LLC con i dati a 78 mesi di BRUKINSA all'ASCO 2026

quotidianodelsud.it·May 27, 2026 · 3 g fa

Alfasigma presenta i primi dati dello studio su filgotinib per il trattamento della spondiloartrite assiale attiva - Il Quotidiano del Sud

morningstar.com·May 27, 2026 · 3 g fa

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

morningstar.com·May 29, 2026 · 1 g fa

Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma

morningstar.com·May 26, 2026 · 4 g fa

Vicore Pharma to Present at the Jefferies Global Healthcare Conference

fiercepharma.com·May 27, 2026 · 2 g fa

Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal

morningstar.com·May 28, 2026 · 2 g fa

Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer

ecodibergamo.it·May 28, 2026 · 1 g fa

BeOne Medicines annuncia i dati di fase 3 HERIZON-GEA pubblicati in NEJM e presentati all'ASCO 2026